Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Halberd Corp (OP: HALB ) 0.0064 UNCHANGED Streaming Delayed Price Updated: 3:43 PM EDT, Aug 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Halberd Corp < Previous 1 2 3 4 5 Next > Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant November 30, 2022 Via ACCESSWIRE Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast Cancer November 17, 2022 Via ACCESSWIRE Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals November 14, 2022 Via ACCESSWIRE Hartman, CEO, and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast October 27, 2022 Via ACCESSWIRE Halberd Laser Therapy Eliminates over 90% of Multiple Antibiotic Resistant Bacteria in Minutes October 18, 2022 Via ACCESSWIRE Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum October 12, 2022 Via ACCESSWIRE Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment September 27, 2022 Via ACCESSWIRE Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment September 27, 2022 Jackson Center, Pennsylvania--(Newsfile Corp. - September 27, 2022) - Halberd Corporation (OTC Pink: HALB) entered into a strategic alliance with AI... Via Newsfile Topics Animal Testing Artificial Intelligence Exposures Animal Testing Artificial Intelligence Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein August 23, 2022 Via ACCESSWIRE NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology August 04, 2022 Via ACCESSWIRE Halberd Corporation Discusses OTCQB Uplisting and Growing List of Proprietary Technologies with The Stock Day Podcast July 28, 2022 Phoenix, Arizona--(Newsfile Corp. - July 28, 2022) - The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB), a publicly... Via Newsfile Topics Intellectual Property Exposures Intellectual Property Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary July 20, 2022 Via ACCESSWIRE Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary July 20, 2022 JACKSON CENTER, PA / ACCESSWIRE / July 20, 2022 / Halberd Corporation (OTC PINK:HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd's patented... From Halberd Corporation Via AccessWire Topics Intellectual Property Exposures Intellectual Property Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron July 14, 2022 Boosts Effectiveness of Commercial Covid Antibodies by 45% From Halberd Corporation Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Halberd Corporation Update, CEO Letter and 2022 Expectations July 12, 2022 Q2 Accomplishments and a Look to the Future From Halberd Corporation Via AccessWire Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer June 21, 2022 JACKSON CENTER, PA / ACCESSWIRE / June 21, 2022 / Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC PINK:HALB) announced the creation of... From Halberd Corporation Via AccessWire Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification June 08, 2022 JACKSON CENTER, PA / ACCESSWIRE / June 8, 2022 / Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the... From Halberd Corporation Via AccessWire Topics Animal Testing Exposures Animal Testing Product Safety Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines May 24, 2022 JACKSON CENTER, PA / ACCESSWIRE / May 24, 2022 / Halberd Corporation (OTC PINK:HALB) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted... From Halberd Corporation Via AccessWire Topics Animal Testing Exposures Animal Testing Product Safety Halberd Engages Professional Firm to Proceed with FDA Filings May 18, 2022 JACKSON CENTER, PA / ACCESSWIRE / May 18, 2022 / Halberd Corporation (OTC PINK:HALB) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug... From Halberd Corporation Via AccessWire Exposures Product Safety Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB May 12, 2022 JACKSON CENTER, PA / ACCESSWIRE / May 12, 2022 / Halberd Corporation (OTC PINK:HALB) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step... From Halberd Corporation Via AccessWire Topics Animal Testing Regulatory Compliance Exposures Animal Testing Legal Product Safety Dr. Gregg Sturrus' TEDx Talk(R) Features Halberd's Extracorporeal Treatment of Neurodegenerative Diseases April 29, 2022 Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. From Halberd Corporation Via AccessWire Halberd CEO Letter April 25, 2022 Q1 Accomplishments and Q2 Plans JACKSON CENTER, PA / ACCESSWIRE / April 25, 2022 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB) This past quarter has witnessed some very... From Halberd Corporation Via AccessWire Halberd Eliminates E. Coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics April 18, 2022 JACKSON CENTER, PA / ACCESSWIRE / April 18, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease... From Halberd Corporation Via AccessWire Topics Animal Testing Exposures Animal Testing Halberd Entering the Medical Metaverse(TM) April 11, 2022 JACKSON CENTER, PA / ACCESSWIRE / April 11, 2022 / Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of non-fungible tokens (NFT's) to monetize certain... From Halberd Corporation Via AccessWire Topics Intellectual Property Exposures Intellectual Property Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression April 04, 2022 JACKSON CENTER, PA / ACCESSWIRE / April 4, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to... From Halberd Corporation Via AccessWire Infectious Disease Specialist Will Guide Halberd's Extracorporeal Elimination of Disease Antigens in Animals and Then Humans March 16, 2022 JACKSON CENTER, PA / ACCESSWIRE / March 16, 2022 / Halberd Corporation (OTC PINK:HALB) announces its entry into the next stage of research. To guide it, having successfully eliminated the Top 10 Target... From Halberd Corporation Via AccessWire Halberd Expands Its Technical Expertise with the Addition of Microbiology Professor March 08, 2022 JACKSON CENTER, PA / ACCESSWIRE / March 8, 2022 / Halberd Corporation (OTC PINK:HALB) is pleased to announce Youngstown State University's (YSU) Dr. Chester R. Cooper has joined its technical team. Dr.... From Halberd Corporation Via AccessWire Halberd's COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant March 01, 2022 Outperforms Approved COVID Antibodies JACKSON CENTER, PA / ACCESSWIRE / March 1, 2022 / Halberd Corporation's (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding... From Halberd Corporation Via AccessWire Exposures COVID-19 Product Safety Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually February 22, 2022 JACKSON CENTER, PA / ACCESSWIRE / February 22, 2022 / Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination... From Halberd Corporation Via AccessWire Halberd Eliminates 100% of Tau Protein From CSF - The 9th of 10 Target Neurodegenerative Disease Antigens February 08, 2022 Tau buildup in the brain is linked to Alzheimer's and other neurodegenerative diseases. JACKSON CENTER, PA / ACCESSWIRE / February 8, 2022 / Halberd Corporation (OTC PINK:HALB) has demonstrated the... From Halberd Corporation Via AccessWire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.